Share on StockTwits

Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Akshay Vaishnaw unloaded 7,890 shares of the stock on the open market in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $85.75, for a total value of $676,567.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of research firms have recently commented on ALNY. Analysts at Deutsche Bank raised their price target on shares of Alnylam Pharmaceuticals from $80.00 to $108.00 in a research note to investors on Friday, January 17th. They now have a “buy” rating on the stock. Separately, analysts at Morgan Stanley downgraded shares of Alnylam Pharmaceuticals from an “overweight” rating to an “equal weight” rating in a research note to investors on Tuesday, January 14th. They now have a $54.00 price target on the stock, down previously from $72.00. Finally, analysts at S&P Equity Research downgraded shares of Alnylam Pharmaceuticals to a “neutral” rating in a research note to investors on Monday, January 13th. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $70.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 3.05% during mid-day trading on Monday, hitting $81.05. The stock had a trading volume of 871,914 shares. Alnylam Pharmaceuticals has a 1-year low of $21.60 and a 1-year high of $112.57. The stock’s 50-day moving average is $70.04 and its 200-day moving average is $58.07. The company’s market cap is $5.141 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, November 6th. The company reported ($0.48) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.39) by $0.09. The company had revenue of $9.00 million for the quarter, compared to the consensus estimate of $8.64 million. During the same quarter last year, the company posted ($0.31) earnings per share. Alnylam Pharmaceuticals’s revenue was down 46.4% compared to the same quarter last year. Analysts expect that Alnylam Pharmaceuticals will post $-1.38 EPS for the current fiscal year.

Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.